---
title: Mr Ng Choon Peng
permalink: /ng-choon-peng/
variant: markdown
description: ""
---
<div class="row">
<div class="col is-3">
<img src="/images/Speakers_NgChoonPeng.png">
</div>
<div class="col is-9 speaker-details">
	<h4><b>Mr Ng Choon Peng</b></h4>
<b>CEO and Co-Founder<br>
ImmunoScape</b>
	
<p>Mr Ng Choon Peng (Choon) is the Co-Founder / CEO of ImmunoScape Pte Ltd, a pre-clinical stage TCR-based therapeutic discovery and development biotech company against solid tumours, leveraging on its Deep Immunomics and Machine Learning platforms.</p>
	
<p>He was appointed by A*STAR to be its President of the A* Global Network, connecting alumni, staff and industry partners to create value. Choon has also been appointed to the National Medical Research Council’s (NMRC) Clinical Trial Infrastructure Review Panel and to the National Health Innovation Centre’s (NHIC) Board Oversight Committee.</p>
	
<p>Previously, Mr Ng was the Senior Director of the PharmBio cluster in A*STAR (Agency for Science, Technology and Research) responsible for formulating Singapore’s Biomedical Research strategy. Choon had an interest to commercialize technology developed by A*STAR’s research institutes.</p>
	
<p>Prior to this, he was CEO Asia for LEO Pharma, a multinational pharmaceutical company headquartered in Denmark. He doubled the business of LEO in 15 Asian countries by breaking new ground in key countries and pushing for professionalism in key functional areas.</p>
	
<p>Mr Ng started his career in the Biopharmaceutical Industry at Johnson and Johnson in the US after his MBA. In Asia, he then rose through the ranks as International Product Manager, Director of Sales and Marketing, and Country Manager. He also started two other companies: Tembusu Healthcare which distributed allergy, respiratory, and dermatology products across a few countries in Asia, and earlier, CrysBio which provided downstream bioprocessing for antibodies in a cheaper and faster way.  Choon successfully exited Tembusu Healthcare through a trade sale to a regional pharmaceutical company in 2021.</p>
</div>
</div>